{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:11:04Z","timestamp":1789132264884,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum disorders. A Bayesian network meta-analysis compared lurasidone to aripiprazole, asenapine, clozapine, olanzapine, paliperidone extended-release (ER), quetiapine, risperidone, and ziprasidone. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause discontinuation, extrapyramidal symptoms (EPS), and akathisia. Results were reported as median differences for continuous outcomes and odds ratios (ORs) for binary outcomes, along with 95% credible intervals (95% CrI). Lurasidone was significantly more efficacious than placebo on the PANSS (\u2212\u20097.95, 95% CrI \u2212\u200911.76 to \u2212\u20094.16) and CGI-S (\u2212\u20090.44, 95% CrI \u2212\u20090.67 to \u2212\u20090.22) scores. Lurasidone was associated with similar weight gain to placebo and statistically significantly less weight gain versus olanzapine (\u2212\u20093.62\u00a0kg, 95% CrI \u2212\u20094.84\u00a0kg to \u2212\u20092.41\u00a0kg), quetiapine (\u2212\u20092.13\u00a0kg, 95% CrI \u2212\u20093.20\u00a0kg to \u2212\u20091.08\u00a0kg), risperidone (\u2212\u20091.16\u00a0kg, 95% CrI \u2212\u20092.14\u00a0kg to \u2212\u20090.17\u00a0kg), asenapine (\u2212\u20090.98\u00a0kg, 95% CrI \u2212\u20091.71\u00a0kg to \u2212\u20090.24\u00a0kg), and paliperidone ER (\u2212\u20090.85\u00a0kg, 95% CrI \u2212\u20091.57\u00a0kg to \u2212\u20090.14\u00a0kg). The odds of all-cause discontinuation were significantly lower for lurasidone than aripiprazole (OR\u2009=\u20090.28, 95% CrI 0.10\u20130.76) and paliperidone ER (OR\u2009=\u20090.25, 95% CrI 0.08\u20130.81) and comparable to other antipsychotics. Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics.<\/jats:p>","DOI":"10.1007\/s00787-019-01425-2","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T22:02:41Z","timestamp":1574460161000},"page":"1195-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-4754","authenticated-orcid":false,"given":"Celso","family":"Arango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Ng-Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"1425_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.jaac.2013.02.008","volume":"52","author":"J McClellan","year":"2013","unstructured":"McClellan J, Stock S (2013) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 52:976\u2013990. https:\/\/doi.org\/10.1016\/j.jaac.2013.02.008","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1425_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","volume":"71","author":"G Masi","year":"2011","unstructured":"Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents. Drugs 71:179\u2013208. https:\/\/doi.org\/10.2165\/11585350-000000000-00000","journal-title":"Drugs"},{"key":"1425_CR3","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/j.1742-1241.2009.02191.x","volume":"63","author":"J Karagianis","year":"2009","unstructured":"Karagianis J, Novick D, Pecenak J et al (2009) Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int J Clin Pract 63:1578\u20131588. https:\/\/doi.org\/10.1111\/j.1742-1241.2009.02191.x","journal-title":"Int J Clin Pract"},{"key":"1425_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.chc.2013.04.001","volume":"22","author":"DI Driver","year":"2013","unstructured":"Driver DI, Gogtay N, Rapoport JL (2013) Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 22:539\u2013555. https:\/\/doi.org\/10.1016\/j.chc.2013.04.001","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"1425_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-244X-10-63","volume":"10","author":"Y-C Kao","year":"2010","unstructured":"Kao Y-C, Liu Y-P (2010) Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry 10:63. https:\/\/doi.org\/10.1186\/1471-244X-10-63","journal-title":"BMC Psychiatry"},{"key":"1425_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.schres.2006.07.007","volume":"88","author":"J Rabinowitz","year":"2006","unstructured":"Rabinowitz J, Levine SZ, H\u00e4fner H (2006) A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 88:96\u2013101. https:\/\/doi.org\/10.1016\/j.schres.2006.07.007","journal-title":"Schizophr Res"},{"key":"1425_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/npjschz.2014.5","author":"CM D\u00edaz-Caneja","year":"2015","unstructured":"D\u00edaz-Caneja CM, Pina-Camacho L, Rodr\u00edguez-Quiroga A et al (2015) Predictors of outcome in early-onset psychosis: a systematic review. Npj Schizophr. https:\/\/doi.org\/10.1038\/npjschz.2014.5","journal-title":"Npj Schizophr"},{"key":"1425_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S2215-0366(18)30057-9","volume":"5","author":"C Arango","year":"2018","unstructured":"Arango C, D\u00edaz-Caneja CM, McGorry PD et al (2018) Preventive strategies for mental health. Lancet Psychiatry 5:591\u2013604. https:\/\/doi.org\/10.1016\/S2215-0366(18)30057-9","journal-title":"Lancet Psychiatry"},{"key":"1425_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrd.2016.28","volume":"15","author":"MJ Millan","year":"2016","unstructured":"Millan MJ, Andrieux A, Bartzokis G et al (2016) Altering the course of schizophrenia: progress and perspectives. Nat Rev Drug Discov 15:485\u2013515. https:\/\/doi.org\/10.1038\/nrd.2016.28","journal-title":"Nat Rev Drug Discov"},{"key":"1425_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T et al (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318\u2013378. https:\/\/doi.org\/10.3109\/15622975.2012.696143","journal-title":"World J Biol Psychiatry"},{"key":"1425_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0706743717720197","volume":"62","author":"S Abidi","year":"2017","unstructured":"Abidi S, Mian I, Garcia-Ortega I et al (2017) Canadian guidelines for the pharmacological treatment of schizophrenia spectrum and other psychotic disorders in children and youth. Can J Psychiatry 62:635\u2013647. https:\/\/doi.org\/10.1177\/0706743717720197","journal-title":"Can J Psychiatry"},{"key":"1425_CR12","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","volume":"18","author":"C Arango","year":"2009","unstructured":"Arango C, Robles O, Parellada M et al (2009) Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18:418\u2013428. https:\/\/doi.org\/10.1007\/s00787-009-0749-5","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"1425_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","volume":"21","author":"D Fraguas","year":"2011","unstructured":"Fraguas D, Correll CU, Merch\u00e1n-Naranjo J et al (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621\u2013645. https:\/\/doi.org\/10.1016\/j.euroneuro.2010.07.002","journal-title":"Eur Neuropsychopharmacol"},{"key":"1425_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaac.2016.12.013","volume":"56","author":"AK Pagsberg","year":"2017","unstructured":"Pagsberg AK, Tarp S, Glintborg D et al (2017) Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56:191\u2013202. https:\/\/doi.org\/10.1016\/j.jaac.2016.12.013","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1425_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40263-015-0308-1","volume":"30","author":"RC Harvey","year":"2016","unstructured":"Harvey RC, James AC, Shields GE (2016) A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 30:27\u201339. https:\/\/doi.org\/10.1007\/s40263-015-0308-1","journal-title":"CNS Drugs"},{"key":"1425_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.euroneuro.2018.03.008","volume":"28","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M et al (2018) Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol 28:659\u2013674. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.03.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"1425_CR17","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295\u2013300","journal-title":"Proc R Soc Med"},{"key":"1425_CR18","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8:336\u2013341","journal-title":"Int J Surg"},{"key":"1425_CR19","volume-title":"CRD\u2019s guidance for undertaking reviews in healthcare","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination (2009) CRD\u2019s guidance for undertaking reviews in healthcare, 3rd edn. York Publication Services, York","edition":"3"},{"key":"1425_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T et al (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7:16","journal-title":"BMC Med Inform Decis Mak"},{"key":"1425_CR21","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"1425_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D (2000) WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10:325\u2013337","journal-title":"Stat Comput"},{"key":"1425_CR23","unstructured":"National Collaborating Centre for Mental Health (2018) Bipolar disorder: the NICE guideline on the assessment and management of bipolar disorder in adults, children and young people. Updated edition. Natl Clin Guidel Number 185. The British Psychological Society and The Royal College of Psychiatrists"},{"key":"1425_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50:683\u2013691","journal-title":"J Clin Epidemiol"},{"key":"1425_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/cap.2006.16.393","volume":"16","author":"T Mozes","year":"2006","unstructured":"Mozes T, Ebert T, Michal S-E et al (2006) An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16:393\u2013403. https:\/\/doi.org\/10.1089\/cap.2006.16.393","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","volume":"63","author":"P Shaw","year":"2006","unstructured":"Shaw P, Sporn A, Gogtay N et al (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721\u2013730. https:\/\/doi.org\/10.1001\/archpsyc.63.7.721","journal-title":"Arch Gen Psychiatry"},{"key":"1425_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/cap.2007.0123","volume":"18","author":"JB Jensen","year":"2008","unstructured":"Jensen JB, Kumra S, Leitten W et al (2008) A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18:317\u2013326. https:\/\/doi.org\/10.1089\/cap.2007.0123","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","volume":"165","author":"RL Findling","year":"2008","unstructured":"Findling RL, Robb A, Nyilas M et al (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432\u20131441. https:\/\/doi.org\/10.1176\/appi.ajp.2008.07061035","journal-title":"Am J Psychiatry"},{"key":"1425_CR29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/cap.2015.0027","volume":"25","author":"RL Findling","year":"2015","unstructured":"Findling RL, Landbloom RP, Mackle M et al (2015) Safety and efficacy from an 8\u00a0week double-blind trial and a 26\u00a0week open-label extension of asenapine in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 25:384\u2013396. https:\/\/doi.org\/10.1089\/cap.2015.0027","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/cap.2011.0092","volume":"22","author":"RL Findling","year":"2012","unstructured":"Findling RL, McKenna K, Earley WR et al (2012) Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 22:327\u2013342. https:\/\/doi.org\/10.1089\/cap.2011.0092","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1089\/cap.2012.0068","volume":"23","author":"RL Findling","year":"2013","unstructured":"Findling RL, Cavu\u015f I, Pappadopulos E et al (2013) Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 23:531\u2013544. https:\/\/doi.org\/10.1089\/cap.2012.0068","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR32","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","volume":"70","author":"J Singh","year":"2011","unstructured":"Singh J, Robb A, Vijapurkar U et al (2011) A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179\u20131187. https:\/\/doi.org\/10.1016\/j.biopsych.2011.06.021","journal-title":"Biol Psychiatry"},{"key":"1425_CR33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1089\/cap.2014.0130","volume":"25","author":"A Savitz","year":"2015","unstructured":"Savitz A, Lane R, Nuamah I et al (2015) Long-term safety of paliperidone extended release in adolescents with schizophrenia: an open-label, flexible dose study. J Child Adolesc Psychopharmacol 25:548\u2013557. https:\/\/doi.org\/10.1089\/cap.2014.0130","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/cap.2008.0144","volume":"19","author":"M Haas","year":"2009","unstructured":"Haas M, Unis AS, Armenteros J et al (2009) A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 19:611\u2013621. https:\/\/doi.org\/10.1089\/cap.2008.0144","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","volume":"48","author":"L Kryzhanovskaya","year":"2009","unstructured":"Kryzhanovskaya L, Schulz SC, McDougle C et al (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60\u201370. https:\/\/doi.org\/10.1097\/CHI.0b013e3181900404","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1425_CR36","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1192\/bjp.bp.107.046177","volume":"194","author":"M Haas","year":"2009","unstructured":"Haas M, Eerdekens M, Kushner S et al (2009) Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 194:158\u2013164. https:\/\/doi.org\/10.1192\/bjp.bp.107.046177","journal-title":"Br J Psychiatry"},{"key":"1425_CR37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/cap.2016.0189","volume":"27","author":"R Goldman","year":"2017","unstructured":"Goldman R, Loebel A, Cucchiaro J et al (2017) Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study. J Child Adolesc Psychopharmacol 27:516\u2013525. https:\/\/doi.org\/10.1089\/cap.2016.0189","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1425_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1177\/0706743717751693","volume":"63","author":"M Coughlin","year":"2018","unstructured":"Coughlin M, Goldie CL, Tranmer J et al (2018) Patient, treatment, and health care utilization variables associated with adherence to metabolic monitoring practices in children and adolescents taking second-generation antipsychotics. Can J Psychiatry 63:240\u2013249. https:\/\/doi.org\/10.1177\/0706743717751693","journal-title":"Can J Psychiatry"},{"key":"1425_CR39","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.1080","author":"M DeHert","year":"2018","unstructured":"DeHert M, Detraux J (2018) The urgent need for optimal monitoring of metabolic adverse effects in children and youngsters who take on-label or off-label antipsychotic medication. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.1080","journal-title":"JAMA Psychiatry"},{"key":"1425_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaac.2014.08.009","volume":"53","author":"C Arango","year":"2014","unstructured":"Arango C, Gir\u00e1ldez M, Merch\u00e1n-Naranjo J et al (2014) Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-na\u00efve patients. J Am Acad Child Adolesc Psychiatry 53:1179\u20131190.e4. https:\/\/doi.org\/10.1016\/j.jaac.2014.08.009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 4","key":"1425_CR41","first-page":"1","volume":"70","author":"DI Velligan","year":"2009","unstructured":"Velligan DI, Weiden PJ, Sajatovic M et al (2009) The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 70(Suppl 4):1\u201346 (quiz 47\u201348)","journal-title":"J Clin Psychiatry"},{"key":"1425_CR42","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S et al (2017) Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat 13:2231\u20132241. https:\/\/doi.org\/10.2147\/NDT.S113099","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1425_CR43","first-page":"401","volume":"18","author":"YP Li","year":"2005","unstructured":"Li YP, Yang XG, Zhai FY et al (2005) Disease risks of childhood obesity in China. Biomed Env Sci 18:401\u2013410","journal-title":"Biomed Env Sci"},{"key":"1425_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1542\/peds.111.1.67","volume":"111","author":"DM Ackard","year":"2003","unstructured":"Ackard DM, Neumark-Sztainer D, Story M, Perry C (2003) Overeating among adolescents: prevalence and associations with weight-related characteristics and psychological health. Pediatrics 111:67\u201374","journal-title":"Pediatrics"},{"key":"1425_CR45","doi-asserted-by":"publisher","first-page":"S471","DOI":"10.1016\/j.euroneuro.2004.08.006","volume":"14","author":"C Arango","year":"2004","unstructured":"Arango C, Parellada M, Moreno DM (2004) Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuropsychopharmacol 14:S471\u2013S479. https:\/\/doi.org\/10.1016\/j.euroneuro.2004.08.006","journal-title":"Eur Neuropsychopharmacol"},{"key":"1425_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M De Hert","year":"2011","unstructured":"De Hert M, Dobbelaere M, Sheridan EM et al (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry J Assoc Eur Psychiatr 26:144\u2013158. https:\/\/doi.org\/10.1016\/j.eurpsy.2010.09.011","journal-title":"Eur Psychiatry J Assoc Eur Psychiatr"},{"key":"1425_CR47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","volume":"165","author":"L Sikich","year":"2008","unstructured":"Sikich L, Frazier JA, McClellan J et al (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420\u20131431. https:\/\/doi.org\/10.1176\/appi.ajp.2008.08050756","journal-title":"Am J Psychiatry"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01425-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-019-01425-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01425-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:46:40Z","timestamp":1605919600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-019-01425-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["1425"],"URL":"https:\/\/doi.org\/10.1007\/s00787-019-01425-2","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"21 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DNg-Mak and A Loebel are employees of Sunovion Pharmaceuticals Inc. E Finn and A Byrne were consultants paid by Sunovion Pharmaceuticals Inc. to conduct the study analysis. C Arango has been a consultant to or has received honoraria or grants from Acadia, Angellini, Gedeon Richter, Janssen Cilag, Lundbeck, Merck, Otsuka, Roche, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}